SPY383.63+6.93 1.84%
DIA315.24+5.66 1.83%
IXIC12,920.15+196.68 1.55%

BRIEF-Johnson & Johnson Announces Submission Of Application To The U.S. FDA For Emergency Use Authorization Of Its Investigational Single-Shot Janssen Covid-19 Vaccine Candidate

BRIEF-Johnson & Johnson Announces Submission Of Application To The U.S. FDA For Emergency Use Authorization Of Its Investigational Single-Shot Janssen Covid-19 Vaccine Candidate

· 02/04/2021 18:15
BRIEF-Johnson & Johnson Announces Submission Of Application To The U.S. FDA For Emergency Use Authorization Of Its Investigational Single-Shot Janssen Covid-19 Vaccine Candidate

- Johnson & Johnson JNJ.N:

  • JOHNSON & JOHNSON ANNOUNCES SUBMISSION OF APPLICATION TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION OF ITS INVESTIGATIONAL SINGLE-SHOT JANSSEN COVID-19 VACCINE CANDIDATE

  • JOHNSON & JOHNSON ANNOUNCES SUBMISSION OF APPLICATION TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION OF ITS INVESTIGATIONAL SINGLE-SHOT JANSSEN COVID-19 VACCINE CANDIDATE

  • J&J - INTENDS TO DISTRIBUTE VACCINE TO U.S. GOVERNMENT IMMEDIATELY FOLLOWING AUTHORIZATION

  • J&J - EXPECTS TO SUPPLY 100 MILLION DOSES TO U.S. IN FIRST HALF OF 2021

  • J&J - EXPECTS TO HAVE PRODUCT AVAILABLE TO SHIP IMMEDIATELY FOLLOWING AUTHORIZATION

  • J&J - WILL SUBMIT A CONDITIONAL MARKETING AUTHORISATION APPLICATION (CMAA) WITH EUROPEAN MEDICINES AGENCY IN COMING WEEKS

  • J&J - INITIATED ROLLING SUBMISSIONS WITH SEVERAL HEALTH AGENCIES OUTSIDE U.S.

Source text for Eikon: ID:nPn7ZRgY0a

Further company coverage: JNJ.N


((Reuters.Briefs@thomsonreuters.com;))